Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 4/2017

01-04-2017 | Rhinology

Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT)

Authors: Kornelia E. C. Wirsching, Frank Haubner, Thomas S. Kühnel

Published in: European Archives of Oto-Rhino-Laryngology | Issue 4/2017

Login to get access

Abstract

The objective of the study was to evaluate the influence of temporary nasal occlusion (tNO) with hypoallergenic tape on the frequency and severity of epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). This prospective observational study included 20 HHT patients who were undergoing Nd:YAG laser therapy at regular intervals. Over a 3-month period, laser therapy was supplemented by tNO with hypoallergenic tape for 5 h/day on average. On a 0–10 numeric rating scale, the patients reported significantly greater satisfaction in epistaxis terms after tNO treatment, with mean scores of 5 before and 7 after 3-month tNO (p = 0.05). The Epistaxis Severity Score also fell significantly from a median of 3.59–2.43 after 3-month tNO compared with laser therapy alone (p = 0.01). The patients’ hemoglobin levels remained stable during the study (median: 12.2 g/dL before tNO; median: 11.7 g/dL after tNO; p = 0.387). Overall, the present study confirms the positive influence of tNO on epistaxis in HHT patients and on subjective satisfaction. This simple and inexpensive strategy is therefore a helpful option, especially in addition to regular Nd:YAG laser therapy, and is recommended by the authors.
Literature
1.
Plauchu H, de Chadarévian JP, Bideau A, Robert JM (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32(3):291–297CrossRefPubMed
2.
Lennox PA, Harries M, Lund VJ, Howard DJ (1997) A retrospective study of the role of the argon laser in the management of epistaxis secondary to hereditary haemorrhagic telangiectasia. J Laryngol Otol 111(1):34–37CrossRefPubMed
3.
Folz BJ, Lippert BM, Wollstein AC, Tennie J, Happle R, Werner JA (2004) Mucocutaneous telangiectases of the head and neck in individuals with hereditary hemorrhagic telangiectasia—analysis of distribution and symptoms. Eur J Dermatol 14(6):407–411PubMed
4.
Gluckman JL, Portugal LG (1994) Modified Young’s procedure for refractory epistaxis due to hereditary hemorrhagic telangiectasia. Laryngoscope 104(9):1174–1177CrossRefPubMed
5.
6.
Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA (2010) An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 120(4):838–843CrossRefPubMed
7.
8.
Kühnel TS, Wagner BH, Schurr CP, Strutz J (2005) Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 19(5):508–513
9.
Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73–87. doi:10.​1136/​jmg.​2009.​069013 CrossRefPubMed
10.
Slotosch D, Koller M, Werner JA, Folz BJ (2006) Recurrent nosebleeds in patients with hereditary hemorrhagic telangiectasia. Dtsch Med Wochenschr 131(11):535–539CrossRefPubMed
11.
Reh DD, Hur K, Merlo CA (2013) Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope 123(4):820–822CrossRefPubMed
12.
Shapshay SM, Oliver P (1984) Treatment of hereditary hemorrhagic telangiectasia by Nd-YAG laser photocoagulation. Laryngoscope 94(12 Pt 1):1554–1556PubMed
13.
Velegrakis GA, Prokopakis EP, Papadakis CE, Helidonis ES (1997) Nd:YAG laser treatment of recurrent epistaxis in heredity hemorrhagic telangiectasia. J Otolaryngol 26(6):384–386PubMed
14.
Werner JA, Lippert BM, Geisthoff UW, Rudert H (1997) Nd:YAG laser therapy of recurrent epistaxis in hereditary hemorrhagic telangiectasia. Laryngorhinootologie 76(8):495–501CrossRefPubMed
15.
Kwaan HC, Silverman S (1973) Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol 107(4):571–573CrossRefPubMed
16.
Shovlin CL, Laila Sulaiman N, Govani FS, Jackson JE, Begbie ME (2007) Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 98(5):1031–1039PubMed
17.
Flanagan BA, Collins C, Parra S (2012) Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. Cutis 89(2):69–72PubMed
18.
Gaillard S, Dupuis-Girod S, Boutitie F, Riviere S, Moriniere S, Hatron PY, Manfredi G et al (2014) Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost 12(9):1494–1502. doi:10.​1111/​jth.​12654 CrossRefPubMed
19.
Geisthoff UW, Schneider G, Fischinger J, Plinkert PK (2002) Hereditäre hämorrhagische Teleangiektasie (Morbus Osler). Eine interdisziplinäre Herausforderung. HNO 50(2):114–128CrossRefPubMed
20.
Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818–828PubMed
21.
Chavan A, Schumann-Binarsch S, Luthe L, Nickau B, Elsasser A, Kuhnel T, Geisthoff U et al (2013) Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). VASA 42(2):106–110CrossRefPubMed
22.
Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85(9):631–632CrossRefPubMed
23.
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A et al (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948–955CrossRefPubMed
24.
Simonds J, Miller F, Mandel J, Davidson TM (2009) The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119(5):988–992CrossRefPubMed
25.
Karnezis TT, Davidson TM (2011) Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121(3):636–638CrossRefPubMed
26.
Rohrmeier C, Sachs HG, Kuehnel TS (2012) A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 269(2):531–536. doi:10.​1007/​s00405-011-1721-9 CrossRefPubMed
27.
Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C (2015) Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck 37(6):783–787CrossRefPubMed
28.
Lund VJ, Howard DJ (1997) Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 111(1):30–33CrossRef
29.
Richer SL, Geisthoff UW, Livada N, Ward PD, Johnson L, Mainka A, Henderson KJ et al (2012) The Young’s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy 26(5):401–404CrossRefPubMed
30.
31.
32.
Al Kadah B, Papaspyrou G, Schneider M, Schick B (2015) First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT). Eur Arch Otorhinolaryngol 272(1):117–122. doi:10.​1007/​s00405-014-3086-3 CrossRefPubMed
33.
Folz BJ, Tennie J, Lippert BM, Werner JA (2005) Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 43(1):40–46PubMed
Metadata
Title
Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT)
Authors
Kornelia E. C. Wirsching
Frank Haubner
Thomas S. Kühnel
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 4/2017
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-016-4431-5

Other articles of this Issue 4/2017

European Archives of Oto-Rhino-Laryngology 4/2017 Go to the issue

Letter to the Editor

Cavernous hemangioma: a term to be canceled

Rhinology

Antibiofilm effects of topical corticosteroids and intranasal saline in patients with chronic rhinosinusitis with nasal polyps depend on bacterial species and their biofilm-forming capacity

Review Article

Ion transport its regulation in the endolymphatic sac: suggestions for clinical aspects of Meniere’s disease

Otology

Diagnostic accuracy of tubomanometry R value in detecting the Eustachian tube pressure equalizing function

Miscellaneous

The effectiveness of combined tonsillectomy and anterior palatoplasty in the treatment of snoring and obstructive sleep apnoea (OSA)

Head and Neck

p16INK4 expression is of prognostic and predictive value in oropharyngeal cancers independent of human papillomavirus status: a Hungarian study